当前位置: X-MOL 学术Mol. Pharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Potential Use of Senolytics for Pharmacological Targeting of Precancerous Lesions
Molecular Pharmacology ( IF 3.6 ) Pub Date : 2021-12-01 , DOI: 10.1124/molpharm.121.000361
Tareq Saleh 1 , Valerie J Carpenter 2
Affiliation  

Senescence is a cell state that contributes to several homeostatic and pathologic processes. In addition to being induced in somatic cells in response to replicative exhaustion (replicative senescence) as part of organismal aging, senescence can also be triggered prematurely by oncogene hyperactivation or tumor suppressor dysfunction [oncogene-induced senescence (OIS)]. Consequently, senescent cells comprise a major component of precancerous lesions of skin, oral mucosa, nasopharynx, prostate, gut, and lung. Unfortunately, invasive (or minimally invasive) interventions are currently the only available approach employed to eradicate premalignant lesions that carry the potential for cancer progression. Senolytics are a newly emerging drug class capable of selectively eliminating senescent cells. Although senolytics have been successfully demonstrated to mitigate a myriad of aging-related pathologies and to cull senescent cancer cells, there is a paucity of evidence for the potential use of senolytics as a novel approach to eliminate oncogene-induced senescent cells. This Emerging Concepts commentary will 1) summarize evidence in established models of OIS including B-Raf–induced nevi, transgenic lung cancer, and pancreatic adenocarcinoma models, as well as evidence from clinical precancerous lesions; 2) suggest that OIS is targetable; and 3) propose the utilization of senolytic agents as a revolutionary means to interfere with the ability of senescent premalignant cells to progress to cancer in vitro and in vivo. If proven to be effective, senolytics will represent an emerging tool to pharmacologically treat precancerous lesions.

中文翻译:

Senolytics 在癌前病变的药理学靶向中的潜在用途

衰老是一种细胞状态,有助于多种稳态和病理过程。除了作为机体衰老的一部分在体细胞中被诱导以响应复制性耗竭(复制性衰老),衰老也可以由癌基因过度激活或肿瘤抑制功能障碍 [癌基因诱导的衰老 (OIS)] 过早触发。因此,衰老细胞是皮肤、口腔黏膜、鼻咽、前列腺、肠道和肺癌前病变的主要成分。不幸的是,侵入性(或微创)干预是目前用于根除具有癌症进展潜力的癌前病变的唯一可用方法。Senolytics 是一种新兴的药物类别,能够选择性地消除衰老细胞。尽管已成功证明 senolytics 可以减轻无数与衰老相关的病理并剔除衰老的癌细胞,但缺乏证据表明 senolytics 作为消除致癌基因诱导的衰老细胞的新方法的潜在用途。该 Emerging Concepts 评论将 1) 总结已建立的 OIS 模型中的证据,包括 B-Raf 诱导的痣、转基因肺癌和胰腺癌模型,以及来自临床癌前病变的证据;2) 建议 OIS 是可定位的;和 3) 提议利用衰老清除剂作为一种革命性的手段来干扰衰老的癌前细胞发展为癌症的能力 缺乏证据表明可能使用 senolytics 作为消除致癌基因诱导的衰老细胞的新方法。该 Emerging Concepts 评论将 1) 总结已建立的 OIS 模型中的证据,包括 B-Raf 诱导的痣、转基因肺癌和胰腺癌模型,以及来自临床癌前病变的证据;2) 建议 OIS 是可定位的;和 3) 提议利用衰老清除剂作为一种革命性的手段来干扰衰老的癌前细胞发展为癌症的能力 缺乏证据表明可能使用 senolytics 作为消除致癌基因诱导的衰老细胞的新方法。该 Emerging Concepts 评论将 1) 总结已建立的 OIS 模型中的证据,包括 B-Raf 诱导的痣、转基因肺癌和胰腺癌模型,以及来自临床癌前病变的证据;2) 建议 OIS 是可定位的;和 3) 提议利用衰老清除剂作为一种革命性的手段来干扰衰老的癌前细胞发展为癌症的能力 以及来自临床癌前病变的证据;2) 建议 OIS 是可定位的;和 3) 提议利用衰老清除剂作为一种革命性的手段来干扰衰老的癌前细胞发展为癌症的能力 以及来自临床癌前病变的证据;2) 建议 OIS 是可定位的;和 3) 提议利用衰老清除剂作为一种革命性的手段来干扰衰老的癌前细胞发展为癌症的能力体外体内。如果证明是有效的,senolytics 将代表一种新兴的药物治疗癌前病变的工具。
更新日期:2021-11-20
down
wechat
bug